NCT05335447

Evaluation of Mass Balance and Absolute Bioavailability of GLPG3667

An Open-label Study in Healthy Male Subjects to Investigate the Metabolism and Excretion Pathways of GLPG3667 Following a Single Oral Dose of [14C]-GLPG3667 and to Determine the Absolute Bioavailability Relative to an Intravenous [14C]-GLPG3667 Microtracer

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: Galapagos NV · Industry
• Sex: Male
• Age: 30 Years – 64 Years
• Healthy volunteers: Accepted

Summary

This is a study in healthy male volunteers to assess how a new test medicine is taken up and broken down by the body as well as its safety and tolerability.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	GLPG3667 capsule	On Day 1, participants will receive a single oral dose of GLPG3667
DRUG	[14C]-GLPG3667 solution for infusion	On Day 1, participants will receive a single microtracer microdose of \[14C\]-GLPG3667 as an intravenous infusion
DRUG	[14C]-GLPG3667 capsule	On Day 1, participants will receive a single oral dose of \[14C\]-GLPG3667

Timeline

• Start date: 2022-04-19
• Primary completion: 2022-06-03
• Completion: 2022-06-03
• First posted: 2022-04-19
• Last updated: 2022-06-30

Locations

1 site across 1 country: United Kingdom